Evidence map›Paper›PMID 40185854›Full record

ArticleScientific reports2025

Influence of preoperative anti TNF alpha antibody therapy on postoperative recurrence of Crohn's disease.

Yuki Sekido, Takayuki Ogino, Takashi Takeda, Mitsunobu Takeda, Tsuyoshi Hata, Atsushi Hamabe, Hidekazu Takahashi, Norikatsu Miyoshi, Mamoru Uemura, Yuichiro Doki and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuki SekidoDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. ysekido@gesurg.med.osaka-u.ac.jp.
Takayuki OginoDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Takashi TakedaDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Mitsunobu TakedaDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Tsuyoshi HataDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Atsushi HamabeDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Hidekazu TakahashiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Norikatsu MiyoshiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Mamoru UemuraDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Yuichiro DokiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Hidetoshi EguchiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Tsunekazu MizushimaDepartment of Therapeutics for Inflammatory Bowel Diseases, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-TNFα antibodies are effective in controlling intestinal inflammation caused by Crohn's disease. However, many patients undergo surgery due to diminished efficacy of the antibodies during maintenance therapy. Currently, the decision between intensification of TNFα therapy and surgery is difficult to make. The purpose of this study was to determine the effect of preoperative treatment with anti-TNFα antibodies on postoperative recurrence of Crohn's disease. One hundred and fourteen consecutive patients with Crohn's disease who underwent bowel resection with anastomosis between 2009 and 2021 were retrospectively analyzed on the preoperative treatment history and perioperative information. Of the 74 patients who used anti-TNFα antibodies preoperatively, 43 underwent surgery after intensification of therapy following attenuation of anti-TNFα antibody efficacy. Time to postoperative endoscopic recurrence was significantly shorter in the group using anti-TNFα antibodies than in the group not using them (p = 0.0055). We found no difference in time to postoperative endoscopic recurrence between patients who underwent intensified therapy and those who underwent immediate surgery. Patients who received preoperative anti-TNFα antibody had a shorter time to postoperative endoscopic recurrence, but the presence or absence of intensified treatment after weakening of the anti-TNFα antibody effects did not affect the time to postoperative endoscopic recurrence.

Indexed as

Crohn DiseaseTumor Necrosis Factor-alphaAdultFemaleHumansMaleMiddle AgedPostoperative PeriodPreoperative CareRecurrenceRetrospective StudiesTreatment OutcomeYoung AdultTumor Necrosis Factor-alphaAnti-TNF alphaCrohn’s diseaseLoss of responsePostoperative recurrencePreoperative treatment

Identifiers

PMID40185854
PMCPMC11971397

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.